A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Glembatumumab vedotin (Primary) ; Capecitabine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms METRIC
- Sponsors Celldex Therapeutics Inc
- 02 Feb 2019 This trial has been completed in UK - MHRA, according to European Clinical Trials Database.
- 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
- 16 Apr 2018 Results published in a Celldex Therapeutics Media Release.